News Lilly takes POINT in radiopharma push Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion.
News Lantheus on POINT in radio-oncology with $2bn licensing deal Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma.
News ACIP backs block on flu vaccines with thimerosal additive The new CDC vaccines committee has voted against the use of thimerosal, a preservative that anti-vaccine activists have linked to autism.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
